OriginalPrevalence of distal diabetic polyneuropathy using quantitative sensory methods in a population with diabetes of more than 10 years’ disease durationPrevalencia de polineuropatía diabética distal según métodos sensoriales cuantitativos en una populación con diabetes mellitus de más de 10 años de duración
Introduction
Distal symmetric diabetic polyneuropathy (DPN) is one of the complications of diabetes. It is the most common presentation of diabetic neuropathy and it presents an insidious and progressive course, resulting in high morbimortality with a negative impact on the patient's quality of life and high social and health care costs.1, 2 Epidemiological studies of its prevalence have yielded very different results: from 22.7% to 54%.3, 4, 5, 6, 7 This discrepancy may be due to various causes, such as heterogeneity of studied diabetic populations and differences in the diagnostic criteria and in methodologies used in the assessment. While neuropathic clinical symptoms have only a limited value for DPN screening, due to their own intrinsically subjective component, the diagnostic criteria recommended by the San Antonio Conference and other authors8, 9 are not always taken in routine practice. On the other hand, the nerve conduction velocity study, despite being the most determinant and reliable test for detecting DPN,10 is not a widely available technique and requires specialized personnel and too much time to perform. Therefore, it is not practical for screening DPN in the clinical routine.
Quantitative sensitive methods allow for the precise determination of the perception thresholds of various sensitivities. They have also proved useful in detecting subclinical DPN and in assessing its severity and progression.11, 12 Some studies have used the vibration perception threshold, measured by biothesiometer, as the reference parameter for the assessment of DPN presence.13, 14 Other sensitivities such as thermal and tactile sensitivities have scarcely been studied with these quantitative procedures,12 thus limiting our knowledge on the actual prevalence of DPN.
Faced with the above mentioned diagnostic difficulties, as well as the limited epidemiological data available based on objective and quantitative methods, and the less well known associated risk factors for DPN, the present work aims to study this prevalence in a diabetic population with more than 10 years of evolution since the diagnosis of diabetes, using a standardized and homogeneous quantitative methodology, objective and measurable, regarding vibratory, thermal and tactile sensitivities, as well as their relationship with other micro- and macroangiopathic complications and with other associated clinical risk factors . As a result we will be better able to determine the actual prevalence of DPN, which is probably higher than is commonly thought, due to the presence of underdiagnosed subclinical neuropathies.
Section snippets
Subjects
One thousand one hundred and fifty-nine ambulatory patients suffering from diabetes mellitus were studied. They were recruited from hospital outpatient clinics in 20 endocrinology units in Spain, during a 6-month period in 2007. These patients met the following inclusion criteria: age ranging from 16 to 70, diagnosis of type 1 or type 2 diabetes mellitus according to the American Diabetes Association (ADA) recommendations, more than 10 years of disease duration, absence of any known
Prevalence of clinical and subclinical DPN
The average age of patients was 49.7±14.8 (SD) years and the average duration of diabetes was 19.6±8.2 (SD) years. From the total of 1011 cases included, 400 met the diagnostic criteria of DPN, while the other 611 had no DPN, which represents 39.6% and 60.4%, respectively. Of the 400 patients with DPN, 253 (63.2%) presented clinical manifestations, while 147 (36.8%) were diagnosed with subclinical DPN as they presented no symptoms.
Variables associated with DPN
When comparing the group of DPN patients (clinical+subclinical)
Discussion
Although the ADA recommendations15 support the use of simple clinical methods for DPN screening—preferably Semmes–Weinstein monofilaments 10 g (1.0 g monofilament provides superior diagnostic sensitivity) and 128 Hz tuning fork—these methods have certain limitations: considerable inter- and intraanalysis variability, subjective interference, lack of universal agreement in the assessment of outcomes and sensitivity far inferior to the diagnostic standard, which is nerve conduction velocity.
Conflict of interest
José M. Miralles-García, Pedro de Pablos-Velasco and Lucio Cabrerizo have no conflict-of-interest to disclose. María Pérez and Vanessa López-Gómez are employed by Pfizer Spain, the company funding this study.
Acknowledgements
This study has been funded by an unrestricted grant from Pfizer Spain that covered the costs of the devices used in the study. The authors want to acknowledge Inmaculada Vilardaga (employed by European Biometric Institute, an independent company contracted by Pfizer to collaborate in data analysis and logistic of the study) for her role in study analysis and statistics interpretation, and to all participating investigators (see Appendices 1), whose collaboration was essential for the conduct of
References (23)
- et al.
Electrophysiologic measures of diabetic neuropathy: mechanism and meaning
Int Rev Neurobiol
(2002) - et al.
Diabetic neuropathy: a review emphasizing diagnostic methods
Clin Neurophysiol
(2003) - et al.
Potential economic benefits of lower-extremity amputation prevention strategies in diabetes
Diabetes Care
(1998) - et al.
Incidence, outcomes and cost of foot ulcers in patients with diabetes
Diabetes Care
(1999) The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups
Diabetologia
(1998)- et al.
The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study
Neurology
(1993) - et al.
A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee
Diabetes Care
(1997) - et al.
Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study
Am J Epidemiol
(1990) - et al.
A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population
Diabetologia
(1993) American Diabetes Association, American Academy of Neurology
Diabetes Care
(1998)
The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias and reproducibility of neuropathic tests
Neurology
Cited by (33)
Prevalence of carpal tunnel syndrome in patients with long-term type 2 diabetes mellitus
2022, HeliyonCitation Excerpt :These patients present lower action potential amplitudes in the median compound muscles and increased sensory thresholds, which have been shown to increase during the ulnar and median nerve stimulations, suggesting broader changes in the peripheral nerve excitability in DM patients with metabolic syndromes [18]. DPN is the most predominant secondary complication in DM, with a prevalence rate ranging between 23% and 54% [19, 20]. In 2020, a nationwide population studies have indicated that DM patients with DPN are more likely to suffer from CTS than those without DPN [3].
Neuropathic pain in individuals with sickle cell disease
2020, Neuroscience LettersCitation Excerpt :The risk factors for neuropathic pain have been defined more clearly in other disease states. In diabetes mellitus, for example, risk factors for neuropathy include age [97], body mass index [44], hypertension [98], smoking, elevated triglyceride levels [99] and waist circumference [100,101]. An observational study of 449 pain-free individuals with HIV demonstrated that the presence of at least one abnormal neuropathic exam finding and history of opiate dependence or abuse was predictive of developing neuropathic pain [102].
Contribution of mitochondria to pain in diabetic neuropathy
2013, Endocrinologia y NutricionDiabetic neuropathy: Clinical manifestations and current treatments
2012, The Lancet NeurologyCitation Excerpt :Pain and autonomic features can improve significantly with time, and this pattern of nerve injury underscores the fact that even rapid improvements in glucose control can lead to neuropathy. A substantial number of patients with diabetes also have asymptomatic neuropathy.19 Thus, while DSP accounts for most neuropathic manifestations in patients with diabetes, there are other important patterns of neuropathy for physicians to consider.